Low T-cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Yong, Michelle K ^a,b,c   Cameron, Paul U ^a,b   Slavin, Monica A ^b,c,d   Cheng, Allen C ^a   Orla Morrissey, C ^a   Bergin, Krystal ^a   Spencer, Andrew ^a   Ritchie, David ^b,d   Lewin, Sharon R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Biomarker; Hematopoietic stem cell transplantation; Mitogen; Mortality; Prognosis; Quantiferon cytomegalovirus; T cell immunity; Transplantation

Indexed keywords

GAMMA INTERFERON; PHYTOHEMAGGLUTININ;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY RATE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROSPECTIVE STUDY; STIMULATION; T LYMPHOCYTE;

EID: 85034040991     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01506     Document Type: Article

References (26)

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 363(22):2091-101. doi:10.1056/NEJMoa1004383
2. Auletta JJ, Lazarus HM. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant (2005) 35(9):835-57. doi:10.1038/sj.bmt.1704966
3. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 369(6):529-39. doi:10.1056/NEJMoa1213299
4. Schlickeiser S, Boes D, Streitz M, Sawitzki B. The use of novel diagnostics to individualize immunosuppression following transplantation. Transpl Int (2015) 28(8):911-20. doi:10.1111/tri.12527
5. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood (2015) 126(1):113-20. doi:10.1182/blood-2015-03-636753
6. Budde K, Matz M, Durr M, Glander P. Biomarkers of over-immunosuppression. Clin Pharmacol Ther (2011) 90(2):316-22. doi:10.1038/clpt.2011.111
7. Tian DM, Wang Y, Zhang XH, Liu KY, Huang XJ, Chang YJ. Rapid recovery of CD3+CD8+ T cells on day 90 predicts superior survival after unmanipulated haploidentical blood and marrow transplantation. PLoS One (2016) 11(6):e0156777. doi:10.1371/journal.pone.0156777
8. Koehl U, Bochennek K, Zimmermann SY, Lehrnbecher T, Sorensen J, Esser R, et al. Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+ CD3+ count reconstitution is associated with survival. Bone Marrow Transplant (2007) 39(5):269-78. doi:10.1038/sj.bmt.1705584
9. Massaro KS, Macedo R, de Castro BS, Dulley F, Oliveira MS, Yasuda MA, et al. Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients? Infection (2014) 42(6):1023-32. doi:10.1007/s15010-014-0685-2
10. Vaughn JE, Storer BE, Armand P, Raimondi R, Gibson C, Rambaldi A, et al. Design and validation of an augmented hematopoietic cell transplantation-comorbidity index comprising pretransplant ferritin, albumin, and platelet count for prediction of outcomes after allogeneic transplantation. Biol Blood Marrow Transplant (2015) 21(8):1418-24. doi:10.1016/j.bbmt.2015.04.002
11. Israeli M, Klein T, Herscovici C, Ram R, Shpilberg O, Sredni B, et al. Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay. Clin Exp Immunol (2013) 172(3):475-82. doi:10.1111/cei.12072
12. Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One (2013) 8(10):e74744. doi:10.1371/journal.pone.0074744
13. Yong MK, Cameron PU, Slavin M, Morrissey CO, Bergin K, Spencer A, et al. Identifying cytomegalovirus (CMV) complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation. J Infect Dis (2017) 215:1684-94. doi:10.1093/infdis/jix192
14. Lee SM, Kim YJ, Yoo KH, Sung KW, Koo HH, Kang ES. Clinical usefulness of monitoring cytomegalovirus-specific immunity by quantiferon-CMV in pediatric allogeneic hematopoietic stem cell transplantation recipients. Ann Lab Med (2017) 37(3):277-81. doi:10.3343/alm.2017.37.3.277
15. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis (2007) 9(2):165-70. doi:10.1111/j.1399-3062.2006.00199.x
16. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant (2008) 8(8):1749-54. doi:10.1111/j.1600-6143.2008.02294.x
17. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 97(4):855-64. doi:10.1046/j.1365-2141.1997.1112925.x
18. Singh KP, Howard JL, Wild SP, Jones SL, Hoy J, Lewin SR. Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. Clin Immunol (2007) 124(2):200-6. doi:10.1016/j.clim.2007.04.018
19. Iacobelli S, Committee ES. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2013) 48(Suppl 1):S1-37. doi:10.1038/bmt.2012.282
20. Anglicheau D, Naesens M, Essig M, Gwinner W, Marquet P. Establishing biomarkers in transplant medicine: a critical review of current approaches. Transplantation (2016) 100(10):2024-38. doi:10.1097/TP.0000000000001321
21. Willis JC, Lord GM. Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol (2015) 15(5):323-9. doi:10.1038/nri3820
22. Nilsson J, Granrot I, Mattsson J, Omazic B, Uhlin M, Thunberg S. Functionality testing of stem cell grafts to predict infectious complications after allogeneic hematopoietic stem cell transplantation. Vox Sang (2017) 112:459-68. doi:10.1111/vox.12521
23. Martinez C, Millan O, Rovira M, Fernandez-Aviles F, Lopez A, Suarez-Lledo M, et al. Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. Int J Hematol (2017) 105(4):497-505. doi:10.1007/s12185-016-2145-5
24. Brunet M, Campistol JM, Diekmann F, Guillen D, Millan O. T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther (2007) 11(4):247-56. doi:10.1007/BF03256246
25. Jo Y, Lim J, Kim Y, Han K, Min WS, Oh EJ. CD4 T-cell function assay using Cylex ImmuKnow and lymphocyte subset recovery following allogeneic hematopoietic stem cell transplantation. Transpl Immunol (2015) 33(2):78-83. doi:10.1016/j.trim.2015.09.001
26. Gesundheit B, Budowski E, Israeli M, Shapira MY, Resnick IB, Bringer R, et al. Assessment of CD4 T-lymphocyte reactivity by the Cylex ImmuKnow assay in patients following allogeneic hematopoietic SCT. Bone Marrow Transplant (2010) 45(3):527-33. doi:10.1038/bmt.2009.182